U.S. markets closed

China Biologic Products Holdings, Inc. (CBPO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
119.54-0.09 (-0.08%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close119.63
Open119.41
Bid0.01 x 1100
Ask120.00 x 1100
Day's Range118.65 - 119.80
52 Week Range97.91 - 120.01
Volume160,647
Avg. Volume166,877
Market Cap4.612B
Beta (5Y Monthly)N/A
PE Ratio (TTM)33.49
EPS (TTM)N/A
Earnings DateMar 10, 2021 - Mar 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est102.78
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
12% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • China Biologic Announces Extraordinary General Meeting of Shareholders
    PR Newswire

    China Biologic Announces Extraordinary General Meeting of Shareholders

    China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that it has called an extraordinary general meeting of shareholders (the "EGM") to be held on March 1, 2021 at 10:00 a.m. (Beijing time), at the principal office of the Company located at 18th Floor, Jialong International Building, 19 Chaoyang Park Road, Chaoyang District, Beijing, China, to consider and vote on, among other matters, the proposal to authorize and approve the previously announced agreement and plan of merger, dated as of November 19, 2020 (the "Merger Agreement"), among the Company, CBPO Holdings Limited ("Parent") and CBPO Group Limited ("Merger Sub"), the plan of merger required to be filed with the Registrar of Companies of the Cayman Islands (the "Plan of Merger") and the transactions contemplated thereby, including the Merger (as defined below).

  • Is CBPO A Good Stock To Buy Now?
    Insider Monkey

    Is CBPO A Good Stock To Buy Now?

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 817 13F filings submitted by hedge funds and prominent investors. These filings show these funds’ portfolio positions as of September 30th, 2020. […]

  • China Biologic Products Inc (CBPO) Q3 2020 Earnings Call Transcript
    Motley Fool

    China Biologic Products Inc (CBPO) Q3 2020 Earnings Call Transcript

    China Biologic announced its third quarter 2020 financial results on November 24th, 2020, after the market closed. Today, you will hear from China Biologic's Chairman and CEO, Mr. Joseph Chow, who will start off the call with a review of the Company's basic operating results and report recent developments. China Biologic's CFO, Mr. Ming Yang, will be available during the Q&A session following the prepared remarks.